Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy

Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia and Ulrike Schick
Journal of Nuclear Medicine April 2024, 65 (4) 630-634; DOI: https://doi.org/10.2967/jnumed.123.266749
Vincent Bourbonne
1Department of Radiation Oncology, University Hospital, Brest, France;
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moncef Morjani
1Department of Radiation Oncology, University Hospital, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Pradier
1Department of Radiation Oncology, University Hospital, Brest, France;
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Hatt
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Jaouen
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
3Institut Mines-Télécom Atlantique, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Solène Querellou
4Nuclear Medicine Department, University Hospital, Brest, France; and
5Groupe d’Étude de la Thrombose Occidentale GETBO (INSERM UMR 1304), Université de Bretagne Occidentale, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitris Visvikis
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Lucia
1Department of Radiation Oncology, University Hospital, Brest, France;
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Schick
1Department of Radiation Oncology, University Hospital, Brest, France;
2LaTIM UMR 1101 INSERM, University Brest, Brest, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (4)
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy
Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
Journal of Nuclear Medicine Apr 2024, 65 (4) 630-634; DOI: 10.2967/jnumed.123.266749

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy
Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
Journal of Nuclear Medicine Apr 2024, 65 (4) 630-634; DOI: 10.2967/jnumed.123.266749
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

Keywords

  • radiation sensitivity
  • KEAP1/NFE2L2
  • PET
  • lung cancer
  • radiomics
SNMMI

© 2025 SNMMI

Powered by HighWire